Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-26T19:43:10.078Z Has data issue: false hasContentIssue false

The New Atypical Antipsychotics

A lack of extrapyramidal side-effects and new routes in schizophrenia research

Published online by Cambridge University Press:  02 January 2018

R. W. Kerwin*
Affiliation:
Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Copyright
Copyright © 1994 The Royal College of Psychiatrists 

References

Altar, C. A., Wasley, A. M., Neale, R. F., et al (1988) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Research Bulletin, 16, 517525.10.1016/0361-9230(86)90181-4Google Scholar
Amsler, H., Leerenhovi, L., Barth, E., et al (1977) Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatrica Scandinavica, 56, 241248.10.1111/j.1600-0447.1977.tb00224.xCrossRefGoogle ScholarPubMed
Andersen, D. H., Nielsen, E. B., Gronvald, F. C., et al (1986) Some atypical neuroleptics inhibit 3H-SCH-23390 binding in vivo. European Journal of Pharmacology, 120, 143144.10.1016/0014-2999(86)90656-4Google Scholar
Angst, J., Bente, D., Heimann, H., et al (1979) Das Klinische Wirkungsbild von clozapine (Untersuchung mit dem Amp system). Pharmacopsychiatry, 4, 201211.10.1055/s-0028-1094313CrossRefGoogle Scholar
Ashby, C. R. Jr & Wang, R. Y. (1990) Effect of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Research, 506, 346348.10.1016/0006-8993(90)91278-OGoogle Scholar
Awouters, F. H. L., Niemegers, C. J. E., Megens, A. H. P., et al (1990) Functional interaction between serotonin S2 and dopamine D2 neurotransmission as revealed by selective antagonism of hypersensitivity to tryptamine and apomorphine. Journal of Pharmacology and Experimental Therapeutics, 254, 945951.Google Scholar
Brezewski, H., Helmchen, H., Hippius, H., et al (1969) Das klinische wirkungspektrum eines nenn dibenzodiazepin derivatives. (W108/47 1854: chloi-11-(4-methyl) Piperazine-5-dibenzo-(b-c) (1,4) diazepine). Aizneimittel forschung, 19, 459496.Google Scholar
Canton, H., Verriele, L. & Colpaert, F. C. (1990) Binding of typical and atypical antipsychotics to 5HT1C and 5HT2 sites. Clozapine potently interacts with 5HT1C sites. European Journal of Pharmacology, 191, 9396.10.1016/0014-2999(90)94100-CCrossRefGoogle ScholarPubMed
Chouinard, G. (1990) A placebo controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica, 82 (suppl. 358), 111120.10.1111/j.1600-0447.1990.tb05301.xCrossRefGoogle Scholar
Claghorn, J., Honigfeld, G., Abuzzahab, F. S., et al (1987) The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377384.10.1097/00004714-198712000-00002Google Scholar
Coward, D. M., Imperato, A., Urwylef, S., et al (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology, 99, 86812.10.1007/BF00442552Google Scholar
Creese, I., Burt, D. R. & Snyder, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481483.10.1126/science.3854Google Scholar
Deutch, A. J., Lee, M. C. & Iadarola, M. J. (1992) Regionally specific effects of atypical neuroleptic drugs on striatal c-fos expression: the nucleus accumbens shell as a focus of antipsychotic action. Molecular and Cellular Neurosciences, 3, 332341.10.1016/1044-7431(92)90030-6Google Scholar
Dugovic, C., Waquier, A. & Janssen, P. A. J. (1989) Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology, 28, 14311433.10.1016/0028-3908(89)90023-3CrossRefGoogle ScholarPubMed
Farde, L., Wiesel, F. A., Stone-Elander, S., et al (1990) D2 dopamine receptors in neuroleptic naive schizophrenic patients. Archives of General Psychiatry, 47, 213219.10.1001/archpsyc.1990.01810150013003CrossRefGoogle ScholarPubMed
Farde, L., Nordstrom, A. L., Wiesel, F. A., et al (1992) Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538544.10.1001/archpsyc.1992.01820070032005CrossRefGoogle ScholarPubMed
Fielding, S. & Lal, J. (1978) Behavioural actions of neuroleptics. Handbook of Psychopharmacology, Vol. 10 (eds L. Iversen, S. Iversen & S. Snyder), pp. 91128. New York: Plenum Press.10.1007/978-1-4613-4042-3_3Google Scholar
Gerlach, J. (1991) New antipsychotics: classification efficacy and adverse effects. Schizophrenia Bulletin, 17, 289309.10.1093/schbul/17.2.289Google Scholar
Gerlach, J. Tharsen, K. & Foy, R. (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal fluid drives haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology, 46, 341350.10.1007/BF00421473Google Scholar
Graybiel, A. M., Moratella, R. & Robertson, H. A. (1990) Amphetamine and cocaine induced drug specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivision of the striatum. Proceedings of the National Academy of Science, USA, 87, 69126916.10.1073/pnas.87.17.6912Google Scholar
Gross, H., Hackl, H. & Kaltenbaeck, E. (1970) Results of a double blind study of clozapine and thioridazine. 7th CINP Congress, Prague.Google Scholar
Hall, H., Sällemurk, M. & Jurninge, E. (1986) Effects of remoxipride and some related new substitute salicylamides on rat brain receptors. Acta Pharmacologica Toxicologia, 58, 6170.10.1111/j.1600-0773.1986.tb00071.xGoogle Scholar
Helmschen, H. (1989) Clinical experience with clozapine in Germany. Psychopharmacology, 99, 880883.Google Scholar
Hogberg, T., Norinder, U., Ramsby, S., et al (1987) New selective dopamine D2 antagonists as neuroleptic agents: chemical and theoretical considerations. Acta Pharmacologica Suecia, 24, 289328.Google Scholar
Hoyer, D., Pazos, A., Probst, A., et al (1986) Serotonin receptors in human brain II. Characterisation and autoradiographic localisation of 5HTk and 5HT2 recognition sites. Brain Research, 376, 97107.10.1016/0006-8993(86)90903-0Google Scholar
Idänpään, H. J., Alhava, E., Olkinnora, M., et al (1977) Agranulocytosis during treatment with clozapine. European Journal of Clinical Pharmacology, 11, 194198.Google Scholar
Imperato, A. & Angelucci, L. (1988) Effects of the atypical neuroleptics clozapine and flupermapine on the in vivo dopamine release in the dorsal striatum and in the prefrontal cortex. (Abstracts of the XVIth CINP congress, Munich.) Psychopharmacology, 45, 780789.Google Scholar
Janssen, P. A. & Van Bever, W. F. M. (1978) Structure activity relationships of the butyrophenones and diphenylbutylpiperidines. In Handbook of Psychopharmacology, Vol. 10 (eds L. Iversen, S. Iversen & S. H. Snyder), pp. 136. New York: Plenum Press.Google Scholar
Janssen, P. A., Niemegers, C. J. E., Awouters, F., et al (1988) Risperidone: a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics, 244, 655693.Google Scholar
Janssen Research Foundation (1990) Risperidone: Investigators' Brochure. Berse: Janssen Research Foundation.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment of resistant schizophrenia: a double blind comparison versus chlorpromazine. Archives of General Psychiatry, 45, 789796.10.1001/archpsyc.1988.01800330013001Google Scholar
Kelly, P. H., Seviour, P. W. & Iversen, S. D. (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Research, 94, 507522.10.1016/0006-8993(75)90233-4CrossRefGoogle ScholarPubMed
Kerwin, R. W. & Lofts, F. J. (1993) Clozapine in the management of schizophrenia. British Medical Journal, 307, 199200.10.1136/bmj.307.6897.199-bGoogle Scholar
King, D. J. & Mills, P. (1993) Clozapine: the Holywell experience with the first 24 patients. Irish Journal of Psychological Medicine, 10, 3034.10.1017/S0790966700013288Google Scholar
Kohler, C., Haglund, L., Ogren, S. O., et al (1981) Regional blockade of neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies. Journal of Neural Transmission, 52, 163173.10.1007/BF01249601Google Scholar
Kohler, C., Daniellson, A., Magnusson, O., et al (1991) Biochemical pharmacology of the atypical neuroleptic remoxipride. Schizophrenia Research, 4, 311328.10.1016/0920-9964(91)90214-CCrossRefGoogle Scholar
Kohler, C., Radesater, A. C., Karlsson-Boethius, G., et al (1992) Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. Journal of Neural Transmission, 87, 4962.10.1007/BF01253110CrossRefGoogle ScholarPubMed
Kramer, M., Roth, T., Salis, P., et al (1978) Relative efficacy of loxapine succinate and thioridazine hydrochloride in the treatment of acute schizophrenia. Current Therapeutic Research, 23, 619631.Google Scholar
Levant, B., Bissette, G., Widerlöv, E., et al (1991). Alterations in residual brain neurotensin concentrations produced by atypical neuroleptic drugs. Regulatory Peptides, 32, 193207.Google Scholar
Lewander, T., Westerbergh, S. E. & Morrison, D. (1990) Clinical profile of remoxipride - a combined analysis of a comparative double blind multicentre trial programme. Acta Psychiatrica Scandinavica, 82 (suppl. 358), 9298.10.1111/j.1600-0447.1990.tb05297.xCrossRefGoogle Scholar
Leysen, J. E., Gommeran, W. E., Eens, A., et al (1992) The biochemical profile of risperidone. Journal of Pharmacology and Experimental Therapeutics, 24, 661670.Google Scholar
Lindstrom, L. H. (1988) The effect of long term treatment with clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica, 77, 524529.10.1111/j.1600-0447.1988.tb05164.xGoogle Scholar
Malmberg, A., Jackson, D. M., Ericksson, A., et al (1993) Unique binding characteristics of neuroleptic agents interacting with human dopamine D2a, D2B and D3 receptors. Molecular Pharmacology, 43, 749754.Google Scholar
Meldrum, B. S. & Kerwin, R. W. (1987) Glutamate receptors and schizophrenia. Journal of Psychopharmacology, 1, 217221.10.1177/026988118700100401Google Scholar
Meltzer, H. Y. (1989a) Clozapine: clinical advantages and biological mechanisms in schizophrenia. In Schizophrenia: A Scientific Focus (ed. Tamminga, C.). New York: Oxford University Press.Google Scholar
Meltzer, H. Y. (1989b) Clozapine: mechanism of action in relation to its clinical advantages. In Recent Advances in Schizophrenia (eds A. Kales, C. N. Stefanos & J. A. Talbott). Heidelberg: Springer.Google Scholar
Mertens, C. (1992) Risperidone treatment in psychotic patients: a combined analysis of the data of three open long term trials. Janssen Clinical Research Report 1992. Berse: Janssen Research Foundation.Google Scholar
Miller, R. J. & Hiley, C. R. (1974) Antimuscarinic properties of neuroleptics and drug induced Parkinsonism. Nature, 248, 596597.10.1038/248596a0Google Scholar
Morrison, D., Englund, A., Lawrie, V., et al (1990) Safety evaluation in both short-term and long-term treatment of schizophrenia with remoxipride. Acta Psychiatrica Scandinavica, 82 (suppl. 358), 164169.10.1111/j.1600-0447.1990.tb05311.xGoogle Scholar
Nutt, D. J. (1990) Specific anatomy, non-specific drugs: the present state of schizophrenia. 5th Biennial Winter Workshop. Journal of Psychopharmacology, 4, 171175.Google Scholar
Nyberg, S., Farde, L., Eriksson, L., et al (1993) 5HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology, 110, 265272.10.1007/BF02251280Google Scholar
Ogren, S. O., Florvall, L., Hall, H., et al (1990) Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatrica Scandinavica, 82 (suppl. 358), 2126.10.1111/j.1600-0447.1990.tb05281.xCrossRefGoogle Scholar
Ogren, S. O., & Goldstein, M. (1993) Phencyclidine and MK801 induced hyperlocomotion are differentially mediated. Neuropsychopharmacology (in press).Google Scholar
Pietzker, A. & Stahl, H. P. (1988) Rezidiuprophylax Behandlungss - trategie und katamestiche. Erhebungen bei perazin-langzeitpatienten. In Therapiemit Neuroleptica-parazin (eds H. Helmehen, H. Hippius & R. Tölle), pp. 149152. Stuttgart: Thieme.Google Scholar
Pilowsky, L., Costa, D. C., Ell, P. J., et al (1992) Clozapine, single photon emission tomography and D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet, 340, 199202.10.1016/0140-6736(92)90467-HGoogle Scholar
Povlsen, J., Noring, N., Fog, R., et al (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatrica Scandinavica, 71, 176185.10.1111/j.1600-0447.1985.tb01268.xGoogle Scholar
Rebec, G. V., Bashore, T. R., Zimmerman, K. S., et al (1980) Neostriatal and mesolimbic neurones: dose dependent effects of clozapine. Neuropharmacology, 19, 281288.10.1016/0028-3908(80)90151-3CrossRefGoogle ScholarPubMed
Reynolds, G. P. (1992) Developments in the drug treatment of schizophrenia. Trends in Neuroscience, 13, 116121.Google Scholar
Reyntjens, A., Gelders, Y. G., Hoppenbrouwers, M. J. J. A., et al (1986) Thymesthemic effects of ritanserin (R55667). A centrally acting serotonin S2 blocker. Drug Development Research, 8, 205211.10.1002/ddr.430080124Google Scholar
Robertson, G. S. & Fibiger, H. C. (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 46, 315328.10.1016/0306-4522(92)90054-6Google Scholar
Sanberg, P. R. (1980) Haloperidol induced catalepsy is medicated by post-synaptic dopamine receptors. Nature, 254, 472473.10.1038/284472a0Google Scholar
Schotte, A., De Bruyckere, K., Janssen, P. F. M., et al (1989) Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Research, 500, 295301.10.1016/0006-8993(89)90325-9Google Scholar
Shaikh, S., Collier, D., Kerwin, R. W., et al (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet, 341, 116.10.1016/0140-6736(93)92594-JGoogle Scholar
Sokoloff, P., Martres, M. P., Giros, B., et al (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochemical Pharmacology, 43, 659666.10.1016/0006-2952(92)90227-AGoogle Scholar
Svestka, J., Ceskova, E., Dysahek, R., et al (1990) Double blind clinical comparison of risperidone and haloperidol in acute schizophrenic and schizophrenic psychosis. Activitas Nervosa Super, 32, 237238.Google Scholar
Van Tol, H. H. M., Bunzow, J. R., Guan, H. C., et al (1991) Cloning of the gene for human D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610619.10.1038/350610a0Google Scholar
Van Tol, H. H. M., Wu, C. M., Guan, H. C., et al (1992) Multiple dopamine D4 receptor variants in the human population. Nature, 358, 149192.Google ScholarPubMed
Walinder, J. & Holm, A. C. (1990) Experiences of long term treatment with remoxipride: efficacy and tolerability. Acta Psychiatrica Scandinavica, 83 (suppl. 359), 8184.Google Scholar
Weinberger, D. R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660667.10.1001/archpsyc.1987.01800190080012Google Scholar
White, L. & Wang, R. Y. (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurones. Science, 221, 10541057.10.1126/science.6136093Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.